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ABSTRACT
Objective: The current objective of the study is to identify some naturally occurring product from Azadirachta indica and evaluate its binding activity 
against VP24 protein as Ebola virus (EBOV) target through in silico docking studies. Reported phytoconstituents of A. indica were prepared for docking 
evaluation using brincidofovir as the standard.
Results: These results showed that all the selected phytoconstituents showed binding energy ranging between -7.95 and -1.54 kcal/mol when 
compared with that of the standard (-6.06 kcal/mol). Naturally occurring products catechin, epicatechin, gallic acid, and nimbolide are potential than 
the standard brincidofovir, but azadirachtin, margolonone, mahmoodin, isomargolonone, gedunin, margolone, nimbidin, and nimbin have low binding 
affinity toward target when compared with the standard.
Conclusion: These molecular docking analyses of phytoconstituents of A. indica could lead to the further development to identify the potent drugs 
for the treatment of EBOV.
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INTRODUCTION
The Ebola outbreak in 2014 is one of the largest viral outbreaks in 
history and the first in West Africa. Ebola virus (EBOV) is a deadly 
pathogenic virus which is classified under Filoviridae family. In 1976, 
it was initially reported in the democratic republic of Congo [5,6]. In 
that capacity, there is no medication or antibody accessible starting 
at now for the treatment of EBOV disease (http://www.physorg.com/
news134840607.html). EBOV encodes seven polypeptides from its 
ribonucleic acid (RNA) genome of ca. 19.0 kb, including glycoprotein, 
nucleoprotein, RNA-subordinate RNA polymerase (L), VP35, VP30, 
VP40, and VP24 [7,8]. Auxiliary network protein VP24 incorporated 
in EBOV is one of the proteins that assume an essential part in Ebola 
infection pathology. Furthermore, a few reviews have perceived VP24 
as a noteworthy destructiveness factor [9,10]. VP24 specifically binds 
to STAT1. STAT1 is a transcription factor involved in the upregulation 
of genes because of the signal by various interferons. Out of these 
proteins, we have concentrated on VP24 protein as the potential 
medication targets investigating the capacity of these proteins to bring 
about defensive resistant reactions to EBOV.
Azadirachta indica prominently known as neem has been widely 
utilized as a part of ayurvedic medication by Indian populace for more 
than 2000 years. It is utilized generally for the recuperating of different 
sicknesses. Natural products and their derivatives give an amazing 
source to new hostile to viral medications [11]. The traditional use 
as antiviral is portrayed for the treatment of creatures experiencing 
bovine and avian pox infection diseases by applying a glue of neem 
leaves specifically on the infected skin [12]. Neem oil can suppress the 
replication of polio infection, and it can restrain dengue infection type 2 
both in vivo and in vitro. Neem bark extract has an immediate hostile to 
HSV-1 property; it has a high antiviral action of confined polysaccharides 
from neem leaves against BoHV-1 replication in HEp-2 cells [13-16].
Based on the above view, the aim of our study is to identify some 
naturally occurring product and evaluate its binding activity against 
VP24 protein as EBOV target through in silico molecular docking 
studies.
METHODS
Glide docking uses the hypothesis of a rigid receptor although scaling 
of van der Waals radii of nonpolar atoms, which decreases penalties 
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Methods: In silico docking studies carried out using grid-based ligand docking with energetics (GLIDE) is a ligand binding program provided
 by Schrödinger.
It  has  been  shown  that  a  lot  of  plant  products  have 
demonstrated  effective  antiviral  activity.  Due  to  their  low 
toxicity and possible multi-step mechanism, which means, lesser 
selective  pressure  for  the  emergence  of  resistant  strains  natural 
products has been encouraged for searching new drugs. In addition,
 the majority of the compounds used for the clinical purpose are
 targeted  for  a  diminutive  number  of  viruses  [1]. 
Ethnopharmacological screenings of the medicinal plants have 
shown  that  a  vast  number  of  phytochemicals  such  as 
alkaloids,  anthraquinones,  coumarins,  flavonoids,  polyphenols,  tannins, 
terpenoids,  among  others,  are  active  against  virus  [2].  The 
antiviral activity of the natural compounds may occur by inhibition
 of one or more steps of viral replication. By direct interaction 
with  the  viral  particle,  they  can  prevent  infection;  change  of  the 
adsorption  venture  by  official  to  cell  receptors;  hindrance  of 
infection infiltration into the host cell, by viewing for pathways of 
actuation  of  intracellular  signs,  and  all  the  more  regularly, 
meddling  with  various  phases  of  viral  replication  [3]. 
High-molecular  weight  compounds  such  as  sulfated 
polysaccharides also contained antiviral activity [4].
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for close contacts, can be used to model a slight “give” in the receptor 
and/or ligand. Docking studies of designed compounds were carried 
out using grid-based ligand docking with energetics (GLIDE) module 
version 5.9. Schrödinger, LLC, New York, NY, 2013. The software 
package running on multiprocessor Linux PC. GLIDE has previously 
been validated and applied successfully to predict the binding 
orientation of many ligands.
Protein structure preparation
The X-ray crystal structures of VP24 (PDB: 4U2X) protein of EBOV 
retrieved from the RCSB Protein Data Bank. Water molecules of 
crystallization were removed from the complex, and the protein was 
optimized for docking using the protein grounding and refinement 
utility provided by Schrödinger LLC.
Ligand structure preparation
The structures of energetic constituents of A. indica (Fig. 1) were 
constructed by means of the splinter dictionary of Maestro 9.3 
(Schrodinger, LLC) using the optimized potentials for liquid simulations-
all atom force field with the steepest descent followed by curtailed 
Newton conjugate gradient protocol.
Glide Score = 0.065*vdW + 0.130*Coul + Lipo + Hbond + Metal + 
BuryP + RotB + Site
RESULTS AND DISCUSSION
The docking investigation was completed for the ligands with the 
target protein VP24 by means of the docking software GLIDE, and the 
docked images are given away in Figs. 2-7. The structures docked by 
GLIDE are usually ranked according to the GLIDE scoring function 
(more negative). The scoring function of GLIDE docking program is 
offered in the G-score form. The most clear-cut method of evaluating 
the precision of a docking procedure is to determine how intimately 
the lowest energy pose (binding conformation) predicted by the 
object scoring function. To study the molecular basis of interaction 
and likeness of binding of ligands to VP24 protein, all the ligands were 
docked into the active site of VP24. The docking result of these ligands 
is prearranged in Table 1.
Fig. 1: Ligand structures from Azadirachta indica
Docking protocol
All  docking  calculations  were  performed  using  the  “extra 
precision” mode of GLIDE program. For the binding site, an
 assortment  of  energy  grids  was  premeditated  and  stored,  is 
distinct  in terms of  two concentric cubes:  The bounding box,  which 
must  contain  the  center  of  any  satisfactory  ligand  pose,  and  the 
enclosing  box,  which  must  contain  all  ligand  atoms  of  an 
satisfactory pose, with a root mean square deviation of <0.5 Å 
and  a  maximum  atomic  displacement  of  <1.3  Å  were  eliminated  as 
unneeded to increase assortment in the retained ligand poses.  The 
scale factor for van der Waals radii was applied to those atoms 
with absolute partial charges ≤0.15 (scale factor of 0.8) and 0.25 
(scale  factor  of  1.0)  electrons  for  ligand  and  protein,  respectively. 
Energy  minimization  protocol  includes  dielectric  constant  of  4.0 
and  1000  steps  of  conjugate  gradient.  Upon  end  of  each  docking 
calculation,  for  the  most  part,  100  poses  per  ligand  were 
generated. The most excellent docked structure be preferred using a
 GLIDE score (G-score) function [17,18].
The  interaction  energy  includes  van  der  Waals  energy, 
electrostatic  energy,  as  well  as  intermolecular  hydrogen bonding  were 
calculated for each minimized complex. The docking score by means of 
GLIDE varied from -1.54 to -7.95 against VP24. The GLIDE score
 for a standard brincidofovir docked with was -6.06. Naturally 
occurring products catechin,  epicatechin,  gallic acid,  and nimbolide 
are  potential  than  the  standard  brincidofovir  and  favipiravir,  but 
azadirachtin, margolonone, mahmoodin, isomargolonone, gedunin,
 margolone,  nimbidin,  and nimbin have low binding likeness 
toward the target when compared with the standard. This proves 
that analogs of catechin, epicatechin, gallic acid, and nimbolide 
could be impending drugs for the target VP24 in antiviral drug 
development for EBOV. In generally, for low 
GLIDE score, good ligand affinity to the receptor may perhaps expect. 
Catechin and epicatechin be evidence for the most excellent inhibition 
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CONCLUSION
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S. No. Compound Glide score
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Fig. 2: Ligand interaction of catechin with VP24 (PDB: 4U2X) protein
Fig. 3: Ligand interaction of epicatechin with VP24 (PDB: 4U2X) 
protein
Fig. 4: Ligand interaction of gallic acid with VP24 (PDB: 4U2X) protein
Fig. 5: Ligand interaction of nimbolide with VP24 (PDB: 4U2X) protein
Fig. 6: Ligand interaction of brincidofovir with VP24 (PDB: 4U2X) 
protein
Fig. 7: Ligand interaction of favipiravir with VP24 (PDB: 4U2X) protein
for the VP24 with -7.95 glide score against VP24 protein receptor. We
 found a fantastic agreement between the localization of the inhibitor on 
docking  and  from  the  crystal  structure  of  the  protein. 
Conformational analysis of different docked complexes also shows 
that residues LYS 61, ASN 63, ARG211, ASN 82, ARG 73, ALA 68, 
and GLN 81 for VP24 protein play imperative role in this receptor’s 
activity.  Docking  studies  performed  by  GLIDE  have  inveterate  that 
above inhibitors fit into the binding pocket of the VP24 receptor. From
 the  results,  we  may  monitor  that  for  successful  docking, 
intermolecular  hydrogen  bonding  and  lipophilic  interactions 
between  the  ligand  and  the  receptor  are  very  significant.  The 
main reason for the increase in GLIDE score is due to the penalties 
for close intraligand contacts.
In  conclusion,  we  have  a  notorious  molecules  catechin, 
epicatechin, gallic acid, and nimbolide, an inventive drug candidate that
 was docked against VP24 protein in a premeditated attempt to 
ascertain a new drug candidate, which is able to obstruct with diverse
 key target points of VP24 in treating EBOV. This compound catechin, 
epicatechin,  gallic  acid,  and  nimbolide  well  calculated  as  a  best 
(lead) molecule and we necessitate design analogs, synthesis and
 evaluate  its  effectiveness  against  viral  disease  caused  by  EBOV 
through the molecular level and in vivo studies.
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